1800 244 735

Helpline (02) 9874 9777

Coming Soon: EuroBuzz 2012

Stand by for EuroBuzz – hot-off-the-press Huntington’s disease research news from the European HD Network Meeting in Stockholm, brought to you by HDBuzz.

EHDN 2012

The European Huntington’s Disease Network (EHDN) is a Europe-wide collaboration of HD professionals, researchers and people affected by HD. EHDN exists to encourage sharing information and ideas about HD, studies and possible treatments, throughout Europe and beyond

EHDN 2012, in Stockholm, Sweden, is the 7th meeting of the whole Network. It’s one of the largest gatherings of HD researchers in the world, and this year’s meeting promises to be the biggest and most exciting EHDN conference yet. Nearly a thousand delegates are expected to attend, and over 300 posters and dozens of fascinating and innovative platform talks will be presented – all dedicated to understanding and developing treatments for Huntington’s disease.

The meeting kicks off this Friday, 14th September, and runs until Sunday 16th.

EuroBuzz!

HDBuzz reporters Dr Ed Wild and Dr Jeff Carroll will be bringing you live updates from the meeting, starting at 9am Swedish time (8am BST / 3am EDT) on Friday 14th September. Follow @hdbuzzfeed on Twitter to get the live feed. We’re calling our coverage EuroBuzz 2012.

Each day, all our updates will be brought together at hdbuzz.net as a single news story.

But wait – there’s more

At the end of each day’s science presentations on Friday 14th and Saturday 15th September, Ed and Jeff will take to the stage to interview the top scientists who’ve presented their research at the meeting. We’ll be getting the lowdown directly, and helping our guests to steer clear of jargon and science-speak.

Video of these live sessions will be available shortly afterwards, at hdbuzz.net.

Get involved

We want you to get involved, by sending us questions to ask our expert guests.

Just follow @hdbuzzfeed on Twitter and send us your question as a tweet.

Our confirmed guests so far are:

    n

  • Dr Ray Truant: the huntingtin protein and how it causes damage

  • n

  • Dr Mike Orth: using advanced scanning techniques to detect brain changes before disease onset

  • n

  • Dr Bev Davidson – gene silencing treatments for Huntington’s disease

  • n

  • Dr Lisa Ellerby – stem cells and how they can help fight HD

  • n

Plus we’ll be covering the controversial topic of diagnosing ‘disease onset’ in HD and phosphodiesterase (PDE) inhibitors, a new and exciting possible approach to treating HD symptoms.

You can also see the program for the whole meeting at the EHDN website, euro-hd.net.

We’re looking forward to three days of great science, and we hope you’ll join us for EuroBuzz 2012!

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Treatment for neurological disorder could be repurposed for Huntington’s disease patients

Published date: 22 October, 2020

While developing a drug called branaplam for patients with SMA, the pharmaceutical company Novartis discovered that it could hold promise for people with HD. The FDA has granted a special status called Orphan Drug Designation to branaplam. An existing drug…for huntingtin lowering? The pharmaceutical company Novartis has announced that the U.S. Food and Drug Administration ... Read more Treatment for neurological disorder could be repurposed for Huntington’s disease patients

Updates from the EHDN Plenary Meeting 2020

Published date: 9 October, 2020

In September, the European Huntington’s Disease Network (EHDN) hosted a virtual webinar event which comprised presentations on some of the latest scientific research as well as clinical studies of Huntington’s disease (HD). Researchers, doctors, patients and other interested folks, tuned in for an afternoon of talks as well as question and answer sessions to learn ... Read more Updates from the EHDN Plenary Meeting 2020

Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

Published date: 23 September, 2020

The SIGNAL clinical trial was designed to test a drug called pepinemab in people with early Huntington’s disease. The key results of that trial were recently announced, and unfortunately, pepinemab did not slow or improve HD symptoms as hoped. What was the SIGNAL trial, and who participated? The SIGNAL trial was launched in 2015 by ... Read more Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

When genes are unstable: targeting somatic instability in HD

Published date: 8 September, 2020

What is somatic instability? We tend to think of DNA as a fixed blueprint, an overarching plan for the biological bricks and bridges that constitute our cells, organs, and bodies. But like any good plan, DNA is actually dynamic and adaptable. It gets frequent use as a template for creating the RNA messages that pave ... Read more When genes are unstable: targeting somatic instability in HD

Working as a team: Changes in brain development mean some brain regions may be slacking off

Published date: 17 August, 2020

The effect of the HD genetic expansion on brain development has been a hot topic in HD research. A team of researchers led by Dr. Sandrine Humbert at the Grenoble Institut Neurosciences, examined human fetal tissue to show that the mutant HD gene causes very early changes in the patterns of early brain development. But ... Read more Working as a team: Changes in brain development mean some brain regions may be slacking off

Caution urged for the use of gene-editing technology CRISPR

Published date: 12 August, 2020

A gene-editing tool known as CRISPR has been heralded as a breakthrough technology for scientists in the lab but also as a potential strategy to treat numerous genetic diseases, including Huntington’s. But a series of recent studies has suggested that CRISPR is less precise than previously thought, leading to unintended changes in the genome. Three ... Read more Caution urged for the use of gene-editing technology CRISPR

Welcome to our new website!

Please bear with us while we iron out the last minute wrinkles! If you have any feedback about our new site, please fill out the form below.